JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Humana (NYSE:HUM) Stock

Humana (NYSE:HUM) had its price objective raised by equities researchers at JPMorgan Chase & Co. from $393.00 to $484.00 in a note issued to investors on Tuesday, Benzinga reports. The brokerage presently has a “neutral” rating on the insurance provider’s stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 10.83% from the company’s current price.

Other research analysts have also recently issued research reports about the company. Evercore raised Humana from an “in-line” rating to an “outperform” rating and set a $480.00 target price on the stock in a research report on Wednesday, July 29th. Guggenheim increased their price target on Humana from $471.00 to $521.00 and gave the company a “buy” rating in a research report on Monday. Barclays raised their price objective on Humana from $582.00 to $587.00 and gave the company an “overweight” rating in a research note on Monday. TD Cowen lifted their price objective on shares of Humana from $350.00 to $370.00 and gave the stock a “hold” rating in a report on Friday, July 31st. Finally, Mizuho upped their target price on shares of Humana from $468.00 to $495.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 13th. Twenty-one investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $469.57.

Humana Stock Up 3.2%

NYSE HUM traded up $13.49 during trading hours on Tuesday, hitting $436.71. The company’s stock had a trading volume of 256,705 shares, compared to its average volume of 1,639,441. The company has a market capitalization of $52.44 billion, a PE ratio of 42.42, a price-to-earnings-growth ratio of 2.57 and a beta of 0.65. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.62. Humana has a 52 week low of $163.11 and a 52 week high of $456.50. The company’s 50-day simple moving average is $404.69 and its two-hundred day simple moving average is $313.04.

Humana (NYSE:HUM) last issued its quarterly earnings data on Friday, November 6th. The insurance provider reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($1.00) by $0.30. The firm had revenue of $41.16 billion during the quarter, compared to analyst estimates of $40.87 billion. Humana had a return on equity of 11.20% and a net margin of 0.88%. The company’s revenue for the quarter was up 26.1% on a year-over-year basis. During the same period in the previous year, the company posted $3.24 EPS. Humana has set its FY 2026 guidance at 9.500- EPS. Research analysts anticipate that Humana will post 9.03 EPS for the current fiscal year.

Institutional Trading of Humana

Institutional investors and hedge funds have recently modified their holdings of the business. Pinnacle Wealth Planning Services Inc. boosted its stake in Humana by 21.8% in the third quarter. Pinnacle Wealth Planning Services Inc. now owns 151 shares of the insurance provider’s stock valued at $58,000 after acquiring an additional 27 shares during the last quarter. Wilkerson Advisory Group LLC increased its stake in shares of Humana by 24.6% during the 2nd quarter. Wilkerson Advisory Group LLC now owns 167 shares of the insurance provider’s stock worth $66,000 after purchasing an additional 33 shares during the last quarter. Moors & Cabot Inc. increased its stake in shares of Humana by 4.3% during the 3rd quarter. Moors & Cabot Inc. now owns 804 shares of the insurance provider’s stock worth $307,000 after purchasing an additional 33 shares during the last quarter. Cidel Asset Management Inc. increased its stake in shares of Humana by 1.1% during the 2nd quarter. Cidel Asset Management Inc. now owns 3,883 shares of the insurance provider’s stock worth $1,542,000 after purchasing an additional 41 shares during the last quarter. Finally, Greenleaf Trust raised its holdings in shares of Humana by 1.7% in the 3rd quarter. Greenleaf Trust now owns 2,524 shares of the insurance provider’s stock worth $963,000 after purchasing an additional 41 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Humana

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Humana reported a narrower Q3 loss and revenue above analyst expectations, then raised its 2026 adjusted EPS guidance. The company cited easing medical costs, supporting expectations for improved profitability. Humana lifts annual profit forecast as medical costs ease
• Positive Sentiment: Analysts raised their price targets after the results: Barclays to $587, Guggenheim to $521 and Cantor Fitzgerald to $495, with each maintaining a bullish rating. Guggenheim has also issued a positive forecast for HUM. Humana Analysts Raise Their Forecasts After Q3 Results Guggenheim Issues Positive Forecast for Humana Stock Price
• Positive Sentiment: A reported rebound in Humana’s Medicare Advantage star ratings could unlock as much as $4.8 billion, potentially supporting future revenue. The article also flags a cost to brokers, tempering the opportunity. Humana’s stars rebound could unlock $4.8bn, but brokers paid a price
• Neutral Sentiment: Humana commenced cash tender offers for eight series of senior notes. The offers involve repurchasing outstanding debt; the announcement provided no immediate change to the company’s earnings outlook. Humana Commences Offers to Purchase for Cash Certain Outstanding Debt Securities

Humana Company Profile

Humana Inc is a U.S. health and wellness company that provides health insurance and healthcare services. Its insurance offerings include Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid and employer-sponsored plans.

The company also provides care through CenterWell, its healthcare services brand, which includes primary care, home health and pharmacy services. Its insurance and care offerings are available in markets across the United States, with availability varying by product and location.

Humana was founded in 1961 as a nursing home company and later expanded into health insurance.